Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Avalo Therapeutics (AVTX) over the last 11 years, with Q3 2025 value amounting to $23.2 million.

  • Avalo Therapeutics' Other Non-Current Liabilities rose 9610.5% to $23.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.2 million, marking a year-over-year increase of 9610.5%. This contributed to the annual value of $8.1 million for FY2024, which is 4630.63% up from last year.
  • As of Q3 2025, Avalo Therapeutics' Other Non-Current Liabilities stood at $23.2 million, which was up 9610.5% from $10.3 million recorded in Q2 2025.
  • In the past 5 years, Avalo Therapeutics' Other Non-Current Liabilities registered a high of $23.2 million during Q3 2025, and its lowest value of $1.4 million during Q3 2021.
  • Its 5-year average for Other Non-Current Liabilities is $6.1 million, with a median of $5.0 million in 2023.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first tumbled by 2780.68% in 2021, then skyrocketed by 17638.19% in 2023.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Other Non-Current Liabilities stood at $2.3 million in 2021, then soared by 110.18% to $4.8 million in 2022, then rose by 14.91% to $5.6 million in 2023, then soared by 46.31% to $8.1 million in 2024, then soared by 185.22% to $23.2 million in 2025.
  • Its Other Non-Current Liabilities was $23.2 million in Q3 2025, compared to $10.3 million in Q2 2025 and $7.7 million in Q1 2025.